Biogen has announced that it is cutting ties with the Alzheimer’s drug Aduhelm, discontinuing its development and commercialization. The drug, which had controversial regulatory approval, was a commercial failure due to low market uptake, safety concerns, and limited insurance coverage. The company is also terminating a post-marketing confirmatory study and has returned the drug’s rights to its developer, Swiss company Neurimmune. Biogen will now focus on the development of Leqembi, another Alzheimer’s drug, as well as other potential treatments for the disease. The decision to discontinue Aduhelm led to job losses and a $60 million charge for closing out the program.
Source link
Biogen Says Goodbye to Beleaguered Alzheimer’s Drug Aduhelm
